Background: Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project. Methods: Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated. Results: Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of 90 days (n ¼ 869), the 5-and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing. Conclusions: We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput "omics" technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.
Introduction
Prostate cancer represents the second and fourth leading cause of cancer incidence and mortality among men worldwide (1.1 M cases were recorded in 2012, resulting in 307,000 deaths). 1 Prostate cancer represents the third and sixth leading cause of cancer incidence and mortality in Japan with 73,145 men diagnosed in 2012 2 and 11,507 prostate-cancer related deaths recorded in 2014. 3 The 10-year relative survival (RS) rate of patients with localized versus metastatic disease was 99.5% versus 19.0%, respectively. 4 Although prostate cancers most frequently arise in the periphery of the prostate gland, no symptom has been identified that can distinguish prostate cancer from benign prostatic hypertrophy. 5 Only once the tumor has grown to compress the urethra or invade the sphincter or neurovascular bundle are symptoms apparent. 6 The risk factors for prostate cancer are still largely undetermined, except for an older age and a family history of the disease. 7 The BioBank Japan (BBJ) project comprises a large cohort of DNA and serum samples from approximately 200,000 patients with 47 diseases and samples. It is anticipated that the patients' clinical and histopathological information will be used in future studies. Herein, we aim to provide an overview of the patients with prostate cancer in the BBJ project.
Materials and methods

Study population
The 
Follow-up
A follow-up survival survey was implemented from 2010 to 2014. Patients' vital status and mortality data were coded according to the International Classification of Disease, tenth revision.
Statistical analyses
First, we described the distribution of time from the initial diagnosis of prostate cancer to entry into the study cohort. Second, we calculated the age-specific distribution of prostate cancer patients in the BBJ project and compared this to the Japanese Ministry of Health, Labor, and Welfare Patient Survey of 2005. 13 Third, the exercise frequency (0, 1e2, or 3 times/week or unknown), and a family history of prostate cancer. Serum PSA levels (<4.0, 4e9, or 10.0 U/mL unknown) were recorded and the clinical stage (Stage IeIV or unknown) and treatment modality (surgery, radiation therapy, or chemotherapy) were also described. Body mass index was calculated as the weight in kilograms divided by the square of the height in meters. Next, the causes of death of patients with prostate cancer were investigated. Additionally, we calculated the Fig. 1 . Distribution of time from the initial diagnosis of prostate cancer to entry into the study cohort.
cumulative survival (CS) rates and RS rates of prostate cancer patients stratified according to clinical stage. To calculate survival rates, we limited our analysis to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of 90 days. CS rates were determined using the KaplaneMeier method. A reference table of survival rate data was obtained from the Cancer 
Results
In this study, 4171 (99.3%) of 4202 prostate cancer patients with histological data available had adenocarcinoma. The distribution of time from the initial diagnosis of prostate cancer to entry into the study cohort is displayed in Fig. 1 . The proportion of patients who enrolled <1, 1, 2, and 3 years after the initial diagnosis of prostate cancer were 33.2%, 27.0%, 12.3%, and 8.0%, respectively. The agespecific distribution of prostate cancer patients is displayed in Fig. 2 respectively. Moreover, the proportion of patients who had undergone chemotherapy for Stage II, III, and IV disease were 2.2%, 6.0%, and 6.2%, respectively ( Table 1 ). The stage-specific distribution of prostate cancer patients stratified according to PSA levels (<4.0, 4.0e9.0, or 10.0 U/mL) is displayed in Fig. 3 . The proportion of Stage II, III, and IV patients with PSA levels of <4.0 and 10.0 U/ mL were 76.4%, 76.8%, and 57.3% and 6.9%, 15.7%, and 32.0%, respectively. The number of cases per person-year of follow-up among all patients and the subgroup with a time from the initial diagnosis of prostate cancer to entry into the study cohort of 90 days were 4424 and 869, respectively. The mortality rate during the study period was approximately 36.9%. The cancer-specific mortality rate was approximately 20.6%. The CS rates of prostate cancer patients are presented in Fig. 4 . The 3-, 5-, and 10-year CS rates were 88.6%, 79.7%, and 64.7%, respectively. The 5-and 10-year RS rates of all patients were 96.3% and 100.5%, respectively. The 5-and 10-year RS rates of patients with Stage II, III, and IV disease were 105.6% and 115.6%, 88.1% and 102.5%, and 79.9% and 60.5%, respectively.
Discussion
In this study, we provide an overview of patients with prostate cancer in the BBJ (a large patient-based) project.
PSA levels are a useful biomarker for risk classification in patients with prostate cancer and patients with localized versus metastatic prostate cancer. 16 Although measurements of PSA levels
were not necessarily obtained at initial diagnosis, our findings suggest that prostate cancer patients with a higher PSA level have a more advanced clinical stage and this was consistent with a previous study. However, a recent Japanese report 17 demonstrated that prostate cancer patients with a PSA level of <3.5 ng/mL at initial diagnosis had a more advanced clinical stage than prostate cancer patients with a PSA level of 3.5e10.0 ng/mL at initial diagnosis. Thus, further epidemiological studies are required to determine the risk classification of prostate cancer patients based on PSA levels at initial diagnosis. Established risk factors for prostate cancer include an older age and a family history of the disease. 7 The life expectancy at birth among Japanese men in 2013 was 80.2 years, one of the highest in the world. Moreover, the incidence and mortality rates of prostate cancer were considerably lower in Japan (22. ) were chosen by the physician, according to the presence or absence of cancer metastases. Due to lack of continuity in medical record keeping in Japan, patients who attended different hospitals for treatment and followup after therapy were likely to have some missing information. Therefore, this is a limitation of our study. A major strength of this study is its large number of patients recruited from hospitals nationwide in Japan. This allowed us to show prevalent prostate cancer patients' characteristics as well as newly diagnosed patients' survival possibility. However, we have to pay caution that many values were missing in our manuscript.
In conclusion, we provide an overview of patients with prostate cancer in the BBJ project. We believe that our findings, coupled with those from various high throughout "omics" technologies using patient DNA and serum samples, will contribute to the implementation of prevention interventions and medical management for prostate cancer, leading to more personalized healthcare in the future.
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